Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease

Bibliographic Details
Main Authors:	Federico Argüelles-Arias, Joaquín Hinojosa-del-Val, Isabel Vera-Mendoza
Format:	Article
Language:	English
Published:	Aran Ediciones
Series:	Revista Espanola de Enfermedades Digestivas
Subjects:	Biosimilar Inflammatory bowel disease SEPD position statement
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082018000600013&lng=en&tlng=en

Similar Items

Position statement on the use of biosimilars in inflammatory bowel disease
by: Emanuel Burri, et al.
Published: (2019-12-01)

Current status of biosimilars in the treatment of inflammatory bowel diseases
by: Dong Il Park
Published: (2016-01-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary
by: Richard H. Parrish
Published: (2021-06-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
by: Marta Vernero, et al.
Published: (2023-10-01)

The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
by: Vered Richter, et al.
Published: (2023-03-01)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
by: Valeria Dipasquale, et al.
Published: (2022-03-01)

FPGA IMPLEMENTATION OF RSEPD TECHNIQUE BASED IMPULSE NOISE REMOVAL
by: M. Rajadurai, et al.
Published: (2013-05-01)

Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)
by: Kang-Moon Lee, et al.
Published: (2015-07-01)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome: The SEPD perspective
by: Isabel Vera, et al.

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal
by: Federico Argüelles-Arias, et al.
Published: (2013-01-01)

Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017-02-01)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017-05-01)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
by: Daniel C. Baumgart, et al.
Published: (2019-03-01)

DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: Natália Sousa Freitas QUEIROZ, et al.
Published: (2020-09-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey
by: Steve Fenwick, et al.
Published: (2019-02-01)

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
by: Thomas Khoo, et al.
Published: (2022-12-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
by: Anna Felis-Giemza, et al.
Published: (2019-10-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
by: Maria-Fernanda Guerra-Veloz, et al.
Published: (2018-09-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
by: Markenson J, et al.
Published: (2017-02-01)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

Los biológicos y los biosimilares
by: Carlos Rios Acosta
Published: (2017-06-01)

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Ten years of biosimilar recombinant human growth hormone in Europe
by: Saenger P
Published: (2017-05-01)

Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
by: C. Gioia, et al.
Published: (2023-12-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Triunfalismo del decreto de los Biosimilares
by: Carlo Vinicio Caballero Uribe
Published: (2014-01-01)